Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(2.02)
# 2,935
Out of 4,761 analysts
41
Total ratings
52.63%
Success rate
2.48%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $120.01 | +24.99% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $35.53 | +125.16% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $7.45 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $74.22 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $12.28 | -2.28% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $54.46 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $88.08 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $3.30 | +960.61% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $109.35 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $644.48 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $36.64 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $120.01
Upside: +24.99%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $35.53
Upside: +125.16%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $7.45
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $74.22
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $12.28
Upside: -2.28%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $54.46
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $88.08
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $3.30
Upside: +960.61%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $109.35
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $644.48
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $36.64
Upside: -